Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752576 | 0.86 | KMT2A (0.43) | ALDH1A1HTTPOLBMEN1KMT2A | |
| SCHEMBL4303757 | 0.85 | ABHD6 (0.41) | ALDH1A1HTTPOLBMEN1KMT2A | |
| SCHEMBL4752523 | 0.85 | ABHD6 (0.43) | ALDH1A1HTTPOLBMEN1KMT2A | |
| SCHEMBL4301342 | 0.78 | ALDH1A1 (0.42) | ALDH1A1POLBMEN1KMT2AABHD6 | |
| SCHEMBL4293508 | 0.78 | ALDH1A1 (0.42) | ALDH1A1POLBMEN1KMT2AABHD6 | |
| SCHEMBL4297012 | 0.78 | MEN1 (0.46) | ALDH1A1HTTMEN1KMT2ALMNA | |
| SCHEMBL4753584 | 0.78 | ALDH1A1 (0.46) | ALDH1A1HTTKMT2ALMNAGAA | |
| SCHEMBL4752095 | 0.77 | ALDH1A1 (0.48) | ALDH1A1POLBLMNAGAA | |
| SCHEMBL4296960 | 0.77 | L3MBTL1 (0.47) | ALDH1A1POLBMEN1KMT2ALMNA | |
| SCHEMBL4753498 | 0.76 | ALDH1A1 (0.48) | ALDH1A1POLBMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | ALDH1A1 388/4885HTT 4390/4885POLB 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.